Skip to content

Posterior Nasal Nerve Neurectomy for Treatment of Intractable Allergic Rhinitis

Posterior Nasal Nerve Surgical Resection Versus Radiofrequency Ablation Versus Surface Coblation for Treatment of Intractable Allergic Rhinitis

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06887842
Enrollment
84
Registered
2025-03-20
Start date
2025-04-25
Completion date
2026-05-01
Last updated
2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable Allergic Rhinitis

Brief summary

This study aims to compare the outcomes of posterior nasal nerve neurectomy in patients with resistant Allergic rhinitis by using three different methods ( surgical resection vs radiofrequency ablation vs surface coblation ) through assesment of functional outcomes, postoperative complications, and impacts on quality of life.

Interventions

DEVICEPosterior Nasal Nerve neurectomy

Posterior Nasal Nerve neurectomy which is done by surgical resection.

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 16 to 65 years, fit for surgery, diagnosed as moderate to severe persistent Allergic Rhinitis, as per the ARIA guidelines having 3 or more of the typical symptoms of Allergic Rhinitis including nasal discharge, repeated attacks of sneezing, nasal itching and nasal obstruction.

Exclusion criteria

* • Patients with Coexisting nasal pathologies that could influence the outcomes of the surgery like: chronic granulomatous diseases of the nose, nasal tumors, chronic sinsitis with or without nasal polyps, etc. * Patients who had used topical steroid nasal spray, oral or topical antihistamines, oral leukotriene antagonists, oral or tobical nasal decongestants in the last 2 weeks. * Immunocompromised patients, Systemic disease affecting prognosis such as diabetes mellitus, hypertension,chronic liver failure or heart failure. * Unwillingness for endoscopic surgery. * Patients younger than 18 years of age. * Patients who are unfit for general anesthesia. * Previous history of nasal surgery

Design outcomes

Primary

MeasureTime frameDescription
Improvement of the four main symptoms (Sneezing ,itching , rhinorrhea ,nasal obstruction)Evaluations will be scheduled for 2 weeks, one month, three months, and six months following surgery.These symptoms will be assessed using the SNOT-22 rhinologic subdomain questionnaire which is routinely and prospectively administered to all patients, and individual item scores within the rhinologic subdomain (need to blow nose, sneezing, runny nose, cough, post- nasal discharge, and thick nasal discharge) will be tabulated, each symptom will be scored on a scale from 0 to 5 (0 = no problem, 1 = very mild problem, 2 = mild problem, 3 = moderate problem, 4 = severe problem and 5 = problem as bad as it can be).

Secondary

MeasureTime frameDescription
postoperative complications eg. Bleeding, crustations etc, postoperative endoscopic score will be evaluated.2 weeks, 1M month after the procedure .Bleeding assessment using The Modena bleeding score. Postoperative endoscopic score including : (discharge, crust formation ,scarring ) after the operation will be also recorded and documented using the LundKennedy (LK) system.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026